510(k) DEN230052
DEN230052 is an FDA 510(k) premarket notification submitted by Senseonics, Incorporated for the device "Eversense AP CGM System". The FDA issued a decision of De Novo Granted on April 29, 2024. The device falls under product code SBA (Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate), a Class II device regulated under 21 CFR 862.1357. Senseonics, Incorporated has at least 1 other 510(k) clearance on record.
Clearance Details
- Decision
- DENG (De Novo Granted)
- Decision Date
- April 29, 2024
- Date Received
- August 9, 2023
- Clearance Type
- Direct
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate
- Device Class
- Class II
- Regulation Number
- 862.1357
- Review Panel
- CH
- Submission Type
An integrated continuous glucose monitoring system (iCGM) with sensor containing dexamethasone acetate is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. The dexamethasone acetate coating is intended to reduce inflammation at the sensor insertion site.